|Title:||5-HT.sub.1A receptor subtype agonist|
|Abstract:|| The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.|
|Inventor(s):|| Jordan; Shaun (Frederick, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamita-Cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP) |
|Assignee:|| Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP) |
|Filing Date:||Jul 01, 2013|
|Claims:||1. A method of treating a patient suffering from obesity, which comprises administering to said patent a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal: ##STR00003## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond. |
2. The method of claim 1 wherein the carbostyril compound is 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl)-3,4-dihydrocarbostyri- l.